Necrostatin-1

Catalog No.S8037

Necrostatin-1 Chemical Structure

Molecular Weight(MW): 259.33

Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 21 Publications

Purity & Quality Control

Choose Selective TNF-alpha Inhibitors

Biological Activity

Description Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells.
Features A powerful tool for characterizing the role of necroptosis with characterized primary target.
Targets
RIP1 [1]
(293T cells)
490 nM(EC50)
In vitro

Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. [1] Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NYnzXoxGS2WubDDWbYFjcWyrdImgRZN{[Xl? MWi1NOKh|ryP NEPzNpkzPMLiaB?= M4XacolvcGmkaYTzJG1OWy2rbnT1Z4VlKGOnbHyg[IVifGh? M3rXZVI3PDd{N{Kz
MEFs  MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mm\GNVDjiIoQvF2= NVfNXmpNPDhiaB?= Mke3SG1UVw>? NX[4d4w{cW6qaXLpeJMhgl[DRD3wdo9ud3SnZDDk[YF1cCCxZjDDUm9VOy2mZYDs[ZRm\CCPRV\z MoD5NlY1Ozd5OEm=
BMDM  NYLHVIFpTnWwY4Tpc44hSXO|YYm= MVqxNOKh|ryP M334TVMxyqCvaX6= NGfXUJdxem:2ZXP0d{Bk\WyuczDmdo9uKFSDS1mtbY5lfWOnZDDMSGghemWuZXHz[S=> NXvlbnZ5OjZ|OEG2NFE>
NCI-H28 NF;PUJpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVLod3RwOTEEoN88US=> NG\mRnIzPMLiaB?= M3v6N5Bz\X[nboTzJGRCWEVvaX7keYNm\CC{ZXT1Z5Rqd25ib3[gUmNKNUh{ODDj[YxtKH[rYXLpcIl1gcLi MVyyOlAxPDF|OB?=
MiaPaCa-2 NUPIV41ETnWwY4Tpc44hSXO|YYm= NE\lflgzOCEQvF2= M{X2UlI1KGh? MmnW[IVkemWjc3XzJJRp\SCnYYLsfUBv\WO{b4TpZ{Bk\Wyucx?= M{LBcVI3ODByNkC3
BxPC-3 NFTuVmhHfW6ldHnvckBCe3OjeR?= Mn61NlAh|ryP NYXyfYtWOjRiaB?= MlXN[IVkemWjc3XzJJRp\SCnYYLsfUBv\WO{b4TpZ{Bk\Wyucx?= Mn7kNlYxODB4MEe=
SGC-7901 M{TmdGNmdGxiVnnhZoltcXS7IFHzd4F6 MYizNOKh|ryP NGWxOHkyyqCq MoCxd5VxeHKnc4Pld{BwgGGuaYDsZZRqdi2vZXTpZZRm\CClZXzsJIRm[XSq MXeyOVc3PzB5Nh?=
KMS-12-PE  MnG0R4VtdCCYaXHibYxqfHliQYPzZZk> MlmzOlAh|ryP MkO0OUBp MWPpcohq[mm2czDTTGsucW6mdXPl[EBk\WyuIHTlZZRp NE\QWW4zPTV|MEC5PC=>
L929-A  NF;3OmlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NH7YXnk2OMLizszNxsA> M{nSRVI1KGh? MWLicI9kc3NiVF7G{tEucW6mdXPl[EBk\WyuIHTlZZRp MXeyOVM6QDV2MB?=
L929-N  M2PSUWNmdGxiVnnhZoltcXS7IFHzd4F6 NGLjenY2OMLizszNxsA> NFPKVJozPCCq MmL3Zoxw[2u|IGTOSu6yNWmwZIXj[YQh[2WubDDk[YF1cA>? NGXxZmYzPTN7OEW0NC=>
L929-A  NYrpR5RDTnWwY4Tpc44hSXO|YYm= NFraeGw2OMLizszNxsA> MXmxNkBp NWLoWXNV[myxY3vzJJRp\SClbHXheoFo\SCxZjDDZZNx[XOnLUOgZY5lKFCDUmC= MX:yOVM6QDV2MB?=
L929-N  M2jPbWZ2dmO2aX;uJGF{e2G7 M3Tje|UxyqEQvF5CpC=> MoTBNVIhcA>? Mm\OZoxw[2u|IITo[UBkdGWjdnHn[UBw\iCFYYPwZZNmNTNiYX7kJHBCWlB? NYLUSos5OjV|OUi1OFA>
L929 M2m4NmZ2dmO2aX;uJGF{e2G7 MmnrOVDDqM7:TdMg MoXQNVIhcA>? NXnRcIpWcW6qaXLpeJMhXE6IzsGtbY5lfWOnZDDCbYQh[2ynYY\h[4U> MVSyOVM6QDV2MB?=
L929-A MUjGeY5kfGmxbjDBd5NigQ>? MUm1NOKh|ryPwrC= NWHnNZJXOTJiaB?= NX[4NG5ncW6qaXLpeJMhfGinIGTOSu6yNWmwZIXj[YQhdG:|czDv[kBucXSxY3jvcoRzcWGuIH3lcYJz[W6nIIDldo1m[WKrbHn0fS=> MUeyOVM6QDV2MB?=
L929 NIi5PVBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX;yfotrOzEEoN88US=> M1LROVHDqGh? M2mx[YlvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJk> MUeyOVA6PTd2Mh?=
L929 NYq0ZWloS2WubDDWbYFjcWyrdImgRZN{[Xl? M2LIdVMxyqEQvF2= MUGxxsBp NV\hclA1cW6qaXLpeJMhXE6ILd8xMYlv\HWlZXSgZ4xm[X[jZ3Wgc4YhXG:ybzDJ MXWyOVA6PTd2Mh?=
Huh7 NI[5PFZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVq1NEDDvU1? Mn;lNlQwPDhiaB?= NV\0Z5FVTE2VTx?= MnuzdJJmfmWwdIOgZ4VtdCCmZXH0bEBw\iC{QXTIR3Yh[29vaX7m[YN1\WRiSIXoO{Bk\Wyucx?= MoXmNlQ6PzN{NEC=
OHC Mn;tSpVv[3Srb36gRZN{[Xl? MofVN|Ax6oDLzszN NGfsUXhFVVOR M3j1UYlv[3KnYYPld{Bvd2m|ZT3pcoR2[2WmIHPvcoRmdnOnZDDueYNt\Wl? NYnEeZFmOjR6N{S3N|Q>
OHC NFzqdWVHfW6ldHnvckBCe3OjeR?= MlzzN|Ax6oDLzszN MX\EUXNQ NYPkdY5V\GWlcnXhd4V{KG6xaYPlMYlv\HWlZXSgd5dwdGynbjDueYNt\WoEoB?= NUTXSVZHOjR6N{S3N|Q>
OHC NYXafolkTnWwY4Tpc44hSXO|YYm= NXzlcYx4OzBy4pEJ{txO NX\lTnpUTE2VTx?= M1\heZJme3WudIOgbY4h[SC{ZXT1Z5Rqd25ib3[gco9qe2VvaX7keYNm\CCUSWCxJIFv\CCUSWCzJIludXWwb3\seY9z\XOlZX7j[S=> NVzMZ|lwOjR6N{S3N|Q>
OHC NGm2eZhHfW6ldHnvckBCe3OjeR?= MlLzN|Ax6oDLzszN MoXKSG1UVw>? M4fJcYRqdWmwaYPo[ZMhdm:rc3WtbY5lfWOnZDDBUXBMKGGldHn2ZZRqd25? NEHQUJYzPDh5NEezOC=>
OHC M4fvTWZ2dmO2aX;uJGF{e2G7 MWmzNFDjiIoQvF2= MVvEUXNQ M1z1eYlv[3KnYYPld{B1cGViboXtZoVzKG:oIHHwc5B1d3SrYzDPTGN{KHerdHjveZQh[Wy2ZYLpcochfGinIHzleoVteyCxZjDDR|gh[W[2ZYKgco9qe2ViZYjwc5N2emV? NVvVb5RKOjR6N{S3N|Q>
SK-Hep1 NVfzNoM3TnWwY4Tpc44hSXO|YYm= NUPuT21xPjEkgJpOwG3DqA>? MVSxPQKBkWh? MnrSZoxw[2u|wrFOtk1t[XCjY3jvcoUucW6mdXPl[EBud3KyaH;sc4dq[2GuIHPoZY5o\SxiY3XscEBl\WG2aDDhcoQhWElidYD0ZYtm NHHld4ozPDh|Mk[wNi=>
SK-Hep1 NE\VfVhHfW6ldHnvckBCe3OjeR?= MXu2NQKBkc7:TdMg MUCxPQKBkWh? NEjyRVlqdmirYnn0d{DPui2OYYDhZ4hwdmVvaX7keYNm\CCuZXHrZYdmKG:oIFjNS2IuOcLi NYG0c|NFOjR6M{K2NFI>
SK-Hep1 MWjGeY5kfGmxbjDBd5NigQ>? M13Qb|Yx6oDLzszNxsA> M4DtRlE56oDLaB?= MULicI9kc3QEoN8yMYxieGGlaH;u[U1u\WSrYYTl[EBRSVJiYXPjeY12dGG2aX;uJIFv\CCDSV[geJJidnOub3PheIlwdiC2bzD0bIUh[3m2b4PvcOKh NITUN3QzPDh|Mk[wNi=>
L-540  MVjGeY5kfGmxbjDBd5NigQ>? M4e1OlYx6oDLzszt NXHrbXd7OeLCiXi= M1jMW5Bz\X[nboTzJJRp\SCpZX7ldoF1cW:wIH;mJHJQWw>? MWqyOFU3OTVzOR?=
L-540  Mne1SpVv[3Srb36gRZN{[Xl? NFHDTnQ3OOLCid88cS=> MVGx5qCKcA>? M4XQZpBz\X[nboTzJJRp\SCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJIRmeG:uYYLpfoF1cW:w NX;aWVMyOjR3NkG1NVk>
L-540  M3nFb2NmdGxiVnnhZoltcXS7IFHzd4F6 M{XlXFYx6oDLzszt MXex5qCKcA>? NGnJSGhz\WS3Y3XzJJRp\SCJaY\pco9{fGG2L2PvdoFn\W6rYj3pcoR2[2WmIHPlcIwh\GWjdHi= MVuyOFU3OTVzOR?=
AGS NHPld|VE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mn;aOlDjiIoQvH2= NGjaN3gy6oDLaB?= M17oSJBz\X[nboTzJJNpcWuxbnnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MofWNlQ1PjNzOUm=
NRK-52E  NH3ZbpZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYT3UVF6OjBizszN NH\aUm8zPCCq M1LpPJBzd3SnY4TzJINmdGy|IH\yc40h[2WubDDk[YF1cCClYYXz[YQh[nliaYPjbIVucWFiaX7qeZJ6 NVPhSmRoOjR|NUG4OFU>
NRK-52E  M4LOeWNmdGxiVnnhZoltcXS7IFHzd4F6 NHX4dlEzOCEQvF2= MkHRNlQhcA>? NFnheoxqdmO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiVF7GMe6yKFO2aX31cIF1cW:wIHHu[EBCXFBiRHXwcIV1cW:w M4HkO|I1OzVzOES1
NRK-52E  NXnKTXV3S2WubDDWbYFjcWyrdImgRZN{[Xl? MVGyNEDPxE1? MnTKNlQhcA>? MV7pcohq[mm2czDpcoNz\WG|ZXSgSJJxOSCycn;0[YlvKGW6cILld5Nqd25iYX\0[ZIhXE6ILd8xJHN1cW23bHH0bY9vKGGwZDDBWHAhTGWybHX0bY9v MXyyOFM2OTh2NR?=
L929 NFzKOppHfW6ldHnvckBCe3OjeR?= NUnibXFMOi93wrFOwIcwdW{EoB?= M3n5VVI1yqCq NUH4ZWlJemW4ZYLz[YQhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JHRPTs7zIHHsc45mKGG|IIflcIwh[XNiVF7G{tHDqCwEoIrWRWQ> MV:yN|k1OTd4OR?=
L929 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDUWGFSOi93wrFOwIcwdW{EoB?= M3HQdlI1yqCq NWH5dYs{emW4ZYLz[ZMhfGinIHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W6mIHPlcIwh\GWjdHigbY5lfWOnZDDifUBVVkcQsTDhcI9v\SCjczD3[YxtKGG|IGTOSu6yyqBtwrD6WmFF NHvkRoozOzl2MUe2PS=>
L929 NHvxV5pHfW6ldHnvckBCe3OjeR?= NIXvT5AzyqEQvHevcYzDqA>? MWCyOOKhcA>? Ml;mdJJwdW:2czDjZZNx[XOnLU[gLJAzOCliYXP0bZZqfHliYX7kJJBzd2Ojc4Dhd4UuPiClbHXheoFo\Q>? MXGyN|k1OTd4OR?=
L929 MnfjSpVv[3Srb36gRZN{[Xl? MVe1xsDPxGdxbXy= M4LZTlI1yqCq MlTlZoxw[2u|IIrWRWQhcW6mdXPl[EBv\WO{b4D0c5NqeyCjbnSgZZV1d3CqYXf5 MXuyN|k1OTd4OR?=
C6 NHHpVVlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4C1[FEhdW2xbD;M NEfQcpM{KGh? NYPaRpBm[XS2ZX71ZZRmeyCVaHnrc45qdiCrbnT1Z4VlKGeuaX;tZUBk\WyuIHTlZZRp NVK5THc2OjN6NEC0OFE>
U87 NVPkUmRbS2WubDDWbYFjcWyrdImgRZN{[Xl? M{G4SFEhdW2xbD;M NGDB[Wc{KGh? M2ezUIF1fGWwdXH0[ZMhW2ira3;ubY4hcW6mdXPl[EBodGmxbXGgZ4VtdCCmZXH0bC=> MWOyN|g1ODR2MR?=
C6 M1HZOmN6fG:2b4jpZ4l1gSCDc4PhfS=> M1ewOFEhdW2xbD;M NFTsZZk{KGh? NITEWFJjdG:la4Ogd4hqc2:waX6gbY5lfWOnZDDu[YNzd3Orcx?= MXKyN|g1ODR2MR?=
U87 NXPtT2ZzS3m2b4TvfIlkcXS7IFHzd4F6 NGOzSHYyKG2vb3yvUC=> MnfWN{Bp NEfuZ2djdG:la4Ogd4hqc2:waX6gbY5lfWOnZDDu[YNzd3Orcx?= MYOyN|g1ODR2MR?=
C6 MWnGeY5kfGmxbjDBd5NigQ>? NF\P[3gyKG2vb3yvUC=> MorkNU42NTNiaB?= MkD1d5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBTUVBvMTDjZZV{\WRiYomgd4hqc2:waX6= MVyyN|g1ODR2MR?=
U87 M4GwZmZ2dmO2aX;uJGF{e2G7 M{fQNFEhdW2xbD;M MUOxMlUuOyCq MmWyd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBTUVBvMTDjZZV{\WRiYomgd4hqc2:waX6= NFTJRlAzOzh2MES0NS=>
TE671 M1fDZ2NmdGxiVnnhZoltcXS7IFHzd4F6 M4joVVQx6oDLzsznM41tyqB? NXnVeFI2OjRiaB?= MnG3doV{[3WnczDHXFE2NTB5MD3pcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJk> NFfBNGYzOzd2NEK5Oi=>
RMS13 MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1X3VFQx6oDLzsznM41tyqB? M1KzS|I1KGh? NWmyTJduemW|Y4Xld{BIYDF3LUC3NE1qdmS3Y3XkJIxwe3Nib3[gZ4VtdCC4aXHibYxqfHl? NYrDU|BMOjN5NESyPVY>
MEFs MnnYR5l1d3SxeHnjbZR6KEG|c3H5 NIr6W4QzNzZxMkCg{txO NXfw[nB2OThiaB?= MnGzbY5pcWKrdIOgWG5H|rFvaX7keYNm\CClZXzsJIRm[XSqIHnuJHJmdEFiS1:gUWVHew>? Ml\kNlM4Ojd3OEG=
MEFs NUnHdWhOTnWwY4Tpc44hSXO|YYm= NXTPZ5p4OjEEoN88US=> MYexM|IwPCCq NG[5NZJ{fXCycnXzd4V{KFSQRt8xMYlv\HWlZXSgVmlRUzFicHjvd5Bpd3K7bHH0bY9v MYqyN|czPzV6MR?=
ΔN-Karpas 299  NVTGUXlwS3m2b4TvfIlkcXS7IFHzd4F6 MnTTNlDDqM7:TR?= MlnvNVYhcA>? NX74[2pEcW6qaXLpeJMhS0R|MD3pcoR2[2WmIHPlcIwh\GWjdHi= MV[yN|U1PTl|OB?=
MM.1S  NGnjeJhEgXSxdH;4bYNqfHliQYPzZZk> M3OzXVkxKML3TR?= NW\4RXkyOSCq NFHjOY5jdG:la4OgRmF[KDFzLUewPFIhcW6mdXPl[EBz[XCrZDDj[YxtKHO5ZXzsbY5o MoSxNlM2OjdzNUS=
KMS-12-BM M33lWWN6fG:2b4jpZ4l1gSCDc4PhfS=> MXy5NEDDvU1? MXmxJIg> MmP0Zoxw[2u|IFLBXUAyOS15MEiyJIlv\HWlZXSgdoFxcWRiY3XscEB{f2WubHnu[y=> M2DZOVI{PTJ5MUW0
HT-22  M2e2ZWNmdGxiVnnhZoltcXS7IFHzd4F6 MmDlNVDDqM7:TR?= MmfpNVLDqGh? MkX6SG1UVw>? MnPLdJJwfGWldIOgZYdicW6|dDDncJV1[W2jdHWtbY5lfWOnZDDj[YxtKGSnYYTo Mk\qNlM{ODd5NUK=
HT-22  NGPmSYpHfW6ldHnvckBCe3OjeR?= M4n1b|I2yqEQvF2= MoXoNQKBmzNywrDtbY4> MXXEUXNQ MX3pcohq[mm2czDFVmshSWO2aY\heIlwdiCrbnT1Z4VlKGK7IHfseZRidWG2ZR?= M3S2XlI{OzB5N{Wy
NIH3T3  Mn\jSpVv[3Srb36gRZN{[Xl? NF7ONGgyOC93MDFOwG0> NYHTOpk2OS9|IHi= M3jtO4Fu\Wyrb4LheIV{KFSQRt8xMYRzcX[nbjDjc41xdGW6IH\vdo1ifGmxbh?= NW\sfY5uOjN{NkG2O|c>
SH-EP M1zDSGFxd3C2b4Ppd{BCe3OjeR?= M13DOVEx6oDLzszNxsA> NInnVYI4OuLCiXlCpC=> NIDBUJpqdmirYnn0d{BKSVBiaX7obYJqfG:{LTDhcoQhVGW6YYT1cZVu[WJvaX7keYNm\CCjcH;weI9{cXN? MkfVNlI5QTB|MkK=
HL60 NFLYbmpCeG:ydH;zbZMhSXO|YYm= NUDh[2J7PjBizszN MYexNkBp NITkSYFmdmijbnPld{B{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NWm1NWNkOjJ6M{e2PFk>
HL60/Adr NHzkV5JCeG:ydH;zbZMhSXO|YYm= NXfRZ|BMPjBizszN Mkj5NVIhcA>? MUjlcohidmOnczDzbIlsd26rbj3pcoR2[2WmIHHwc5B1d3Orcx?= MXWyNlg{PzZ6OR?=
K562 Mme2RZBweHSxc3nzJGF{e2G7 MUi2NEDPxE1? NWLBRVFVOTJiaB?= M{PkfoVvcGGwY3XzJJNpcWuxbnnuMYlv\HWlZXSgZZBweHSxc3nz M1XMV|IzQDN5Nki5
K562/Adr  MVXBdI9xfG:|aYOgRZN{[Xl? MX62NEDPxE1? NEjJdY4yOiCq NILDToJmdmijbnPld{B{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NHjhdG0zOjh|N{[4PS=>
HL60 MUPGeY5kfGmxbjDBd5NigQ>? M{LmOVYxKM7:TR?= NX7iXGpnOTJiaB?= MoHjZZVodWWwdIOgeIhmKGOjc4Dhd4UuOyCjY4Tpeol1gQ>? M17kT|IzQDN5Nki5
HL60/Adr NUjKdZI3TnWwY4Tpc44hSXO|YYm= MWm2NEDPxE1? NUPK[VBkOTJiaB?= M2PlbIF2\22nboTzJJRp\SClYYPwZZNmNTNiYXP0bZZqfHl? MnzHNlI5Ozd4OEm=
K562 NXTuNnh5TnWwY4Tpc44hSXO|YYm= M1TuO|YxKM7:TR?= MmDhNVIhcA>? MWrheYdu\W62czD0bIUh[2G|cHHz[U0{KGGldHn2bZR6 MX2yNlg{PzZ6OR?=
K562/Adr  MoHUSpVv[3Srb36gRZN{[Xl? NULmSZIzPjBizszN NYnSNGhFOTJiaB?= NXz2emIy[XWpbXXueJMhfGinIHPhd5Bie2VvMzDhZ5Rqfmm2eR?= MknZNlI5Ozd4OEm=
HL60 NUHGfVhJTnWwY4Tpc44hSXO|YYm= MWq2NEDPxE1? M17DbFEzKGh? NH;uO21qdmO{ZXHz[ZMhfGinIHHjeIl3cXS7IH;mJINie3Cjc3XzMEBk[XOyYYPlJFgh[W6mIEm= NUPzbo1[OjJ6M{e2PFk>
HL60/Adr NX3IN|V6TnWwY4Tpc44hSXO|YYm= NEXYWJA3OCEQvF2= NEG3VWUyOiCq M1jGS4lv[3KnYYPld{B1cGViYXP0bZZqfHlib3[gZ4F{eGG|ZYOsJINie3Cjc3WgPEBidmRiOR?= NUTIPIR6OjJ6M{e2PFk>
K562 MXTGeY5kfGmxbjDBd5NigQ>? M3PlSlYxKM7:TR?= NWjJPJlyOTJiaB?= MlvobY5kemWjc3XzJJRp\SCjY4Tpeol1gSCxZjDjZZNx[XOnczygZ4F{eGG|ZTC4JIFv\CB7 M4e1[FIzQDN5Nki5
K562/Adr  NFXNWVRHfW6ldHnvckBCe3OjeR?= MV[2NEDPxE1? NEj1V4kyOiCq NFrRXHVqdmO{ZXHz[ZMhfGinIHHjeIl3cXS7IH;mJINie3Cjc3XzMEBk[XOyYYPlJFgh[W6mIEm= MmnCNlI5Ozd4OEm=
L929sA M1vKcWFxd3C2b4Ppd{BCe3OjeR?= MVOxNEDPxE1? M3vielEhcA>? NGjOVJhqdmirYnn0d{B1cGViYYDvdJRwfGmlIILld5BwdnOnIITvJHRPTg>? M1\V[|IzOzZ{N{[3
L929sA M{HzR2Fxd3C2b4Ppd{BCe3OjeR?= NYjCbWZYOTBizszN NEW1R28yKGh? M4fv[JJme2O3ZYOgZ4VtdHNiZYjwdoV{e2mwZzDSTXBMOc7WSVSg[pJwdSCWTl[tbY5lfWOnZDDhdI9xfG:|aYO= MlvJNlI{PjJ5Nke=
L929sA M4HWcWFxd3C2b4Ppd{BCe3OjeR?= M4Ple|ExKM7:TR?= MoTRNUBp NV3HZ3RK[WK{b3fheIV{KHSqZTDpcpRmemGldHnvckBw\iClYYPwZZNmNThid3n0bEBHSUSG NUDT[FZ1OjJ|NkK3Olc>
TPC-1 NYWwd2M{S2WubDDWbYFjcWyrdImgRZN{[Xl? MXKxNFAh|ryP NFm0OmgzPCCq M3f2dmROW09? MmOzbY5kemWjc3XzJINmdGy3bHHyJJN2en[rdnHs NHzDT3ozOjF|NkixPC=>
8505c MkTBR4VtdCCYaXHibYxqfHliQYPzZZk> MYexNFAh|ryP NILlWJUzPCCq MVrEUXNQ Mnr0bY5kemWjc3XzJINmdGy3bHHyJJN2en[rdnHs MmnhNlIyOzZ6MUi=
SW13 MlK0R4VtdCCYaXHibYxqfHliQYPzZZk> MUSxNFAh|ryP NW\u[2I{OjRiaB?= NUTReFAyTE2VTx?= M{LYTIlv[3KnYYPld{Bk\WyudXzhdkB{fXK4aY\hcC=> NYXlRWRzOjJzM{[4NVg>
Jurkat  NXfRWYg5S3m2b4TvfIlkcXS7IFHzd4F6 MoPoOVAwKDFyMD:yNFDDqM7:bR?= NFjofXoyNzNiaB?= MnfjdoVlfWOnc9MgUoFm\2yncnnhJIZwf2yncnmtbY5lfWOnZDDjfZRwfG:6aXPpeJk> M3rXbVIyPTN3MEKw
Jurkat  MWXGeY5kfGmxbjDBd5NigQ>? NUHMfWY2OjBywrFOwI0> M1z1R|MxKG2rbh?= M2\OUJJm\HWlZYRCpG5i\WeuZYLpZUBnd3euZYLpMYlv\HWlZXSgdoVi[3SrdnWgc5h6\2WwIIPw[YNq\XNiKGLPV{kh\2WwZYLheIlwdg>? MYOyNVU{PTB{MB?=
HT-22 NVjCenhMS3m2b4TvfIlkcXS7IFHzd4F6 MlzzNVAh|ryP NEjvV5AyOiCq MoXodJJwfGWldIOgZYdicW6|dDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhPcLibX3vcE9NKGeudYThcYF1\cLi NUP2Xm9JOTd5NkC4Olk>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Immunofluorescence
RIP1 / RIP3 ; 

PubMed: 30462730     


Immunofluorscence data showed an increased expression of RIP1 and RIP3 in Pg-LPS group and an eminent reduction of RIP1 in the Pg-LPS+Nec-1 group.

30462730

Protocol

Kinase Assay:

[1]

+ Expand

RIP1 kinase assay:

Phosphorylation of RIP1 requires its kinase activity. Expression constructs of FLAGtagged wild-type (WT) or a kinase-inactive pointmutant of RIP1 (K45M) are are transfected into 293T cells and RIP1 kinase assay is performed as described in the Methods in the presence of [γ-32P]ATP for 30 min at 30℃. Samples are subjected to SDS-PAGE and RIP1 band is visualized by autoradiography. Relative intensities of radioactive bands are quantified and are shown (ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads is subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein amounts in kinase reactions.
Cell Research:

[2]

+ Expand
  • Cell lines: Jurkat, BALB/c 3T3, SV40-transformed MEF, L929
  • Concentrations: 0.01-100 μM
  • Incubation Time: --
  • Method:

    Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC6 for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 51 mg/mL warmed (196.66 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 259.33
Formula

C13H13N3OS

CAS No. 4311-88-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

TNF-alpha Signaling Pathway Map

Related TNF-alpha Products

Tags: buy Necrostatin-1 | Necrostatin-1 supplier | purchase Necrostatin-1 | Necrostatin-1 cost | Necrostatin-1 manufacturer | order Necrostatin-1 | Necrostatin-1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID